Minoxidil-Induced Hypertrichosis in a Child with Alopecia Areata
Sir, Here, we are reporting development of severe hypertrichosis in a 3-year-old child with alopecia areata secondary to topical minoxidil, a commonly used off-label topical therapy for the same.
A 3-year-old male child developed acute onset multiple bald patches diffusely distributed over the scalp (30% scalp area), along with loss of eyebrows. Parents started twice daily application of 5% minoxidil lotion on suggestion of a chemist and continued the same for more than 2 months without any dermatological consultation. No standard method of application of minoxidil was followed and it was applied as ordinary hair oil (2 times a day in liberal amount, 3 bottles of 60 ml were used in 2 months). There was no significant improvement in bald patches; however, slowly the boy developed hypertrichosis over forehead, cheek and neck [Figures 1 and 2] . No other cutaneous or systemic side-effects were noticed by parents during minoxidil use. No other topical or systemic medications (such as steroids) were used before or during minoxidil use. General physical and cutaneous examination of the child was within normal limit, excluding any other systemic cause for hypertrichosis. No serum hormonal investigations were performed due to lack of clinical indication. Parents were counselled regarding the cause of excessive hair growth and advised to discontinue minoxidil use.
Pharmacologically, minoxidil, originally manufactured as an antihypertensive drug, is mainly used for alopecia. It affects hair growth through various plausible mechanisms such as increased duration of the anagen growth phase, agonistic effects on adenosine-triphosphate (ATP)-sensitive potassium channels, and prostaglandin stimulation in the dermal papillae. Though it is primarily approved for androgenetic alopecia of both sexes, its off-label uses include topical application in alopecia areata.
There have been several reports of systemic administration of minoxidil either by oral administration to the mother during pregnancy or by oral ingestion by the child, leading to diffuse hypertrichosis of the newborn and children. [1, 2] Hypertrichosis is also a common side effect of topical minoxidil use more commonly seen in women. Systemic absorption of the drug is <2% with topical therapy. It is usually localized to the head and neck; it may occasionally involve other body areas. [3] [4] [5] Severe affection by topical use, as in our case, is uncommonly reported. [6] Hypertrichosis caused by topical minoxidil depends on various factors such as higher amount or concentration of application, excessive systemic absorption, and high sensitivity of the follicular apparatus to minoxidil. In our patient, the high dose and unsupervised application (both in terms of concentration and daily quantity) in combination with the patient's low body weight and age favored the development of hypertrichosis.
The efficacy of topical minoxidil in alopecia areata has never been definitively proven. Because of higher chances of adverse effects, use of topical minoxidil should be Letters to the Editor discouraged in the pediatric age group. If required, lower concentration (2%) of minoxidil in gel-based formulation should be used in pediatric age group because of relative safety. Over the counter sale of minoxidil should be restricted completely or to a minimum concentration of preparation.
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Laugier-Hunziker Syndrome in a Young Female
Sir, Laugier-Hunziker syndrome (LHS) is a rare, acquired, disorder of pigmentation characterized by hyperpigmentation of lips, oral mucosa, and longitudinal melanonychia. The disease is a diagnosis of exclusion and is diagnosed mainly on the basis of clinical and histopathological features. This benign disease mostly manifests in adults with no systemic features or malignant potential. Early identification of LHS helps in ruling out other severe syndromes associated with mucocutaneous hyperpigmentation and malignant potential such as Peutz-Jeghers syndrome. A 19-year-old female attended our department with a history of hyperpigmentation on nails of fingers and toes with longitudinal melanonychia, which had developed gradually over the last 8-9 years [ Figure 1a and b]. Patient also complained of pigmentation on the lower lip and tongue for the last 5 years [ Figure 2a ]. Hyperpigmented lesions were also present over the soft and hard palate. There were no ulcers in the mouth, and orodental hygiene was good. Examination of hands and feet showed hyperpigmented macules over the tips of all fingers and toes. The volar aspect of finger tips and soles also had few pigmented macules [ Figure 2b ]. She was otherwise healthy with no complaints of any abdominal pain, diarrhoea, vomiting, fatigue, and weight loss; she was not receiving any medication (including antimalarials or minocycline). No family history of any mucocutaneous disorder was present. There was no history of any trauma prior to the pigmentation. General physical and systemic examination was normal. Routine hematological and biochemical investigations were within normal limits. Serum cortisol level was also normal. X-ray of the chest, ultrasound of the abdomen, endoscopy, and echocardiography were normal. The histopathology of skin biopsy taken from the plantar lesion showed hyperkeratosis and acanthosis [ Figure 3a ]. Basal cell hyperpigmentation was scanty with few melanocytes [ Figure 3b ]. Patient was diagnosed as a classical case of LHS. LHS is a rare disorder which was first described by Laugier and Hunziker in 1970. [1] It is an acquired, benign pigmentary skin condition characterized by diffuse oral hypermelanosis with pigmentation of the nails and longitudinal melanonychia. [2] Cutaneous manifestations can also be present in other areas of body and the term "idiopathic lenticular mucocutaneous pigmentation" has also been used. [3] This syndrome
